Results 111 to 120 of about 516,619 (288)

Hemophilia A: An Ideal Disease for Prenatal Therapy

Prenatal Diagnosis, EarlyView.
ABSTRACT Hemophilia A (HA) is the most common inherited coagulation defect. Current state‐of‐the‐art treatment consists of frequent administration of prophylactic infusions of coagulation factor VIII (FVIII) protein or bispecific antibodies that replace the cofactor function of FVIIIa to maintain hemostasis. However, these treatments are far from ideal,
Christopher D. Porada, Anthony Atala, Graça Almeida‐Porada   +2 more
wiley   +1 more source

Long‐term outcomes of haploidentical hematopoietic stem cell transplantation with antithymocyte globulin–based myeloablative conditioning in pediatric refractory or relapsed non‐Hodgkin lymphoma

Pediatric Investigation, EarlyView.
Single‐center retrospective data showed that ATG‐based myeloablative haploidentical hematopoietic stem cell transplantation provides durable remission and favorable long‐term survival in children with refractory/relapsed non‐Hodgkin lymphoma, achieving high engraftment rates, low relapse incidence, and acceptable toxicity.
Chenguang Jia, Jie Zheng, Meng Yuan, Hongbo He, Yibo Fan, Bin Wang, Guanghua Zhu, Jun Yang, Yanhui Luo, Lixiao Cai, Pan Zhang, Yanlong Duan, Maoquan Qin   +12 more
wiley   +1 more source

Precision immunomodulation for pediatric hemophagocytic lymphohistiocytosis in intensive care

Pediatric Investigation, EarlyView.
This review presents a bedside framework for recognizing pediatric hemophagocytic lymphohistiocytosis and cytokine storm, stabilizing organ dysfunction, identifying the underlying phenotype, selecting targeted immunomodulation, considering extracorporeal adjuncts, and reassessing response within 24–72 h. ABSTRACT Hemophagocytic lymphohistiocytosis (HLH)
Weerapong Lilitwat, Prakreeti Bhandari
wiley   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

The fibroblast-driven melanoma/Treg vitiligo mouse model is effectively suppressed by IFNγ blocking antibody

Frontiers in Medicine
The use of immunosuppressive drugs for vitiligo treatment carries a potential risk of increased infection, whereas IFNγ bispecific antibodies represent an alternative therapeutic strategy.
Yuhua Xie, Jun Cui, Yanhua Lu, Yingxue Du, Jianmin Chang   +4 more
doaj   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering

VIEW, EarlyView.
This study systematically organizes the evolution of diagnostic antibodies from discovery platforms to design‐oriented engineering and analyzes the strengths and limitations of each approach. Meanwhile, it provides a critical, literature‐driven synthesis of current challenges, proposing integrated strategies for assay‐aware and function‐driven antibody
Qitao Song, Lulai Xu, Weilin Wu, Fei Xie, Yantong Pan, Tiantian Yang, Xiaoxia Xu, Yanyin Lin, Lihua Zhang, Jiahui Zhou, Junyou Zhou, Linping Li, Zhanhui Wang, Weijing Yi, Jing Wang   +14 more
wiley   +1 more source

IL-17/TNF-? BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS

, 2020
Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic inflammation causing swelling in the joints. IL17/TNF-? bispecific antibodies are antibodies that can bind to two different types of epitopes and work on two different types ...
Adnan, Muhammad Luthfi
core   +1 more source

Identification and engineering of potent bispecific antibodies that protect against herpes simplex virus recurrent disease

Cell Reports
Summary: Herpes simplex virus (HSV) causes lifelong infections, including oral and genital herpes. There is no vaccine, and current antivirals are only partially effective at reducing symptoms and transmission.
Chingwei V. Lee, Hector Viadiu, Apurva Kalamkar, David I. Bernstein, Andrew Pae, Xinchao Yu, Sylvia Wong, Fernando J. Bravo, Sheng Ding, Elbert Seto, Magdeleine Hung, Yu Yu, Weimei Xing, Giuseppe A. Papalia, Wei Kan, Brian Carr, Majlinda Thomas, Leah Tong, Priyanka Desai, Nadine Jarrousse, Alexandre Mercier, Meghan M. Holdorf, Simon P. Fletcher, Emma Abernathy   +23 more
doaj   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source